Refine by
Tumor Tissue Articles & Analysis
67 news found
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of its new Tumor Organoid & CAF Co-culture services to provide researchers with a more physiologically relevant in vitro tumor model, enabling a deeper understanding of tumor-stromal interactions and the development ...
Breast cancer remains one of the most challenging diseases to treat, especially for aggressive forms such as triple-negative breast cancer. Researchers are working relentlessly to better understand tumor metabolism and to find new therapeutic strategies. Two recent studies highlight how critical glutamine metabolism is in breast cancer cells: ...
SOPHiA GENETICS offers a comprehensive suite of liquid biopsy applications that have helped progress oncology research and tumor mutation profiling. Liquid biopsy testing offers an alternative to solid tumor testing by isolating cell-free DNA (cfDNA) from blood plasma, which may uncover circulating tumor DNA (ctDNA). ...
This tissue microarray includes various artery tissues (coronary, aorta, etc.) and atherosclerosis samples. ...
Through this partnership, we aim to provide researchers with the tools and expertise needed to accelerate their research efforts in developing liver models for drug discovery, accurate cancer models for precision medicine, and exploring the potential of combining light and extrusion bioprinting modalities to advance tissue engineering.” Prof. Shaochen Chen added, ...
ByCELLINK
Peptide-drug conjugates (PDCs) are mainly used in anti-cancer therapy, which integrates the advantages of small molecular weight, high tumor penetration, low immunogenicity, large-scale synthesis using solid phase synthesis, low production cost, relatively good pharmacokinetics, and so on. Peptides selected for PDCs can specifically target protein receptors overexpressed in ...
An inhibition of DGKzeta has been demonstrated to enhance T-cell priming against suboptimal tumor antigens and has the potential to overcome multiple immune-suppressive mechanisms in the tumor microenvironment. ...
ByBayer AG
xCures, Inc. is proud to announce their partnership with RenovoRx, a clinical-stage biopharmaceutical company that focuses on fighting cancer through localized treatment of difficult-to-treat tumors, such as pancreatic adenocarcinoma. Through this collaboration, xCures will help eligible pancreatic cancer patients access a Phase III clinical study entitled, Targeted ...
ByxCures
BNCT is a targeted radiation cancer therapy in which neutron beams interact with a boron-bearing compound, taken up selectively by tumors, to create DNA-damaging alpha particles within the tumor cells, sparing neighboring, healthy tissue. BNCT has the potential to deliver highly effective, cell-localized radiation therapy to treat ...
Cancer Vaccine Development Based on pMHC Cancer vaccines to enhance the immune response, target tumor-specific mutations not present in normal tissues, and eradicate tumors. Vaccine Development Based on VLPs with MHC Complex To demonstrate and deliver specific tumor-associated MHC complex antigens and create more scalable and ...
The publications addressed that the majority of druggable targets that drive oncogenic vulnerability are not expressed in a uniform or homogeneous manner throughout tumor tissue. Thus, intratumoral heterogeneity, as observed among the cells of an individual tumor, poses a major challenge in targeted therapy selection in oncology practice. ...
Northstar Response is a methylation-based, tissue-agnostic treatment response monitoring assay. Using our molecular counting technology, the assay provides absolute quantification of methylated circulating tumor DNA (ctDNA) burden. ...
The majority of PROTACs were created with ligands that recruit E3 ligases, which are widely expressed in tumors and normal tissues, and these PROTACs can cause off-target toxicity if the target protein is not tumor-specific. The development of tumor-specific/selective PROTACs will benefit from identifying those E3 ligases that ...
“Our MOS technology supports the development of new insights into tumor microenvironments and heterogeneity of the originating tumor tissue for accurate, rapid and high-throughput therapeutic profiling. ...
It is estimated that more than 240,000 cases of brain and nervous system tumors are diagnosed each year around the world. The most common and most lethal of these cancerous tumors are glioblastoma (GBM). ...
Actym Therapeutics, a privately held biotechnology company developing STACT, a novel therapeutic platform that delivers immunomodulatory payloads to solid tumors after IV dosing, announced today the significant expansion of its senior leadership team. ...
BNCT is a targeted radiation cancer therapy in which neutron beams destroy only boron compound-bearing tumors without destroying neighboring normal tissue. BNCT has the potential to deliver highly effective and cell-localized radiation therapy to treat tumors with minimal impact on the patient’s quality of life compared to other radiation, ...
Biomarkers have been shown to help identify patients who are most likely to benefit from treatment with immunotherapies, such as PD-1/PD-L1-targeted therapies. Still, the gold standard of tumor tissue PD-L1 staining, as well as other biomarkers, such as tumor mutational burden, do not always accurately predict the efficacy of these therapies in ...
Understanding the cellular heterogeneity of tissues such as tumors is crucial for both translational and clinical research. ...
ACTM-838 is Actym's lead clinical development candidate for the treatment of solid tumors. The therapeutic candidate is based on the company's immunotherapy platform called STACT (S. Typhimurium-Attenuated Cancer Therapy), which delivers active compounds directly to tumor-resident immune cells. "Manufacturing of ACTM-838 is an important milestone for our company. ...